Loading stock data…
INSM
$133.26-3.07 (-2.25%)
Market ClosedLast close May 1
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Insmed Incorporated in the Healthcare sector is trading at $133.26. The stock is currently 37% below its 52-week high of $212.75, remaining 14.2% below its 200-day moving average. Technical signals show oversold RSI of 26 and bearish MACD signal, explaining why INSM maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 26) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$133.26
Potential Upside
5%
Whystock Fair Value$139.92
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus20 analysts
Mean target$212.70+59.6%
Range$177.00 – $243.00
Fundamentals
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial l...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.89B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-139.97%
Volume
Today's trading volume
1.56M
Recent News
Raymond James Starts Insmed (INSM) at Outperform, Citing Limited Competition
Insmed Incorporated (NASDAQ:INSM) is one of the Stocks that Billionaire Druckenmiller and Jim Cramer like. On April 9, 2026, Raymond James initiated coverage of Insmed Incorporated (NASDAQ:INSM) with an Outperform rating. The firm’s analyst set a price target of $200 on the stock. According to the analyst’s research note, the early launch of Brinsupri has […]
Vanguard’s Larger Passive Stake Puts Insmed’s Volatile Story In Focus
Vanguard Capital Management has reported an increased passive ownership stake in Insmed (NasdaqGS:INSM) through a Schedule 13G filing. The disclosure signals higher institutional involvement in the company and updates the public record on Insmed's shareholder base. Insmed, trading on the NasdaqGS under the ticker INSM, recently closed at $133.26. The share price reflects a mixed return profile, with a 1 year gain of 84.3% alongside a 24.8% decline year to date and a 19.2% decline over the...
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates
Cartesian Therapeutics, Inc. (RNAC) delivered earnings and revenue surprises of -73.81% and -81.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Insmed Incorporated (INSM) PT Lifted to $230 as Guggenheim Updates Biotech Earnings Models
We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. Insmed Incorporated is one of the best biotech stocks. TheFly reported on April 16 that Guggenheim Securities increased its price target on INSM from $227 to $230 while maintaining a Buy rating. The adjustment was made within a broader […]